Colchicine + Interferon-Beta + Aspirin + Rivaroxaban
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus
Conditions
Coronavirus, Severe Acute Respiratory Syndrome
Trial Timeline
Apr 21, 2020 → Dec 30, 2022
NCT ID
NCT04324463About Colchicine + Interferon-Beta + Aspirin + Rivaroxaban
Colchicine + Interferon-Beta + Aspirin + Rivaroxaban is a phase 3 stage product being developed by Bayer for Coronavirus. The current trial status is completed. This product is registered under clinical trial identifier NCT04324463. Target conditions include Coronavirus, Severe Acute Respiratory Syndrome.
What happened to similar drugs?
0 of 11 similar drugs in Coronavirus were approved
Approved (0) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04324463 | Phase 3 | Completed |
Competing Products
20 competing products in Coronavirus